Developments in NRG1 Fusion+ Cancers | Special Issues

Dr. Tolba on Targeting NRG1 Fusions With Afatinib

September 25, 2019

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the potential to target NRG1 fusion–positive lung adenocarcinoma with afatinib (Gilotrif).

Afatinib Generates Excitement in NRG1 Fusion+ Lung Cancer, But Challenges Remain

September 24, 2019

Early data suggest that afatinib (Gilotrif) is a potentially effective treatment option for patients with lung adenocarcinoma who have NRG1 fusions, but the identification of these fusions continues to pose a challenge.

Afatinib Shows Potential in NRG1-Positive Gastrointestinal Cancers

August 01, 2019

Benjamin Weinberg, MD, provides insight into NRG1 fusions, the effectiveness of afatinib in patients harboring these fusions, and future research being done in NRG1 fusion–positive gastrointestinal cancers.